Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000385
English
Authors' recommendations:
Sildenafil (Revatio®) is recommended, within its current licensed indication, as an option for use within NHS Wales for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity.
AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH in association with a National Commissioning Group designated expert centre.
AWMSG is of the opinion that sildenafil (Revatio®) is not suitable for shared care between primary and secondary care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=160863&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Piperazines
- Hypertension, Pulmonary
- Antihypertensive Agents
- Sulfones
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.